Moderna's Trading Volume Plummets 55.89% Ranking 372nd Amid Stock Decline

On May 7, 2025, Moderna's trading volume reached $259 million, a significant decrease of 55.89% from the previous day, ranking 372nd in the day's stock market activity. Moderna's stock price fell by 1.51%, marking the second consecutive day of decline, with a total decrease of 13.58% over the past two days.

Moderna's combined Covid and flu mRNA shot has shown promising results in a phase 3 clinical trial, outperforming existing standalone vaccines for both viruses. The study, involving 8,000 participants, demonstrated that the combo shot produced a stronger immune response against COVID-19 and most strains of flu in individuals aged 50 and older. The side effects reported were mild, including injection site pain, fatigue, and headaches.

Moderna believes that mRNA technology could accelerate the production of flu shots compared to traditional methods that rely on chicken eggs or cell cultures. The company is optimistic about the potential of mRNA to enhance vaccination rates and improve public health outcomes. The study, published in the Journal of the American Medical Association, provides evidence that the combo shot can offer temporary disease protection, as measured by antibody levels in participants' blood after 29 days.

Moderna has adjusted its target date for the vaccine's approval to 2026, following a request from the Food and Drug Administration for more direct measures of the shot's efficacy in reducing disease risk. The company continues to invest in mRNA technology, aiming to develop innovative solutions for public health challenges.